Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026

Turn Therapeutics Inc.

2026-Q1 EPS reported -$0.03

Cash and equivalents $11.2M as of March 31, 2026, up from $5.1M at Dec 31, 2025.
Net loss $970,972 ($0.03 basic EPS) vs $328,547 ($0.01) in Q1 2025.
G&A expenses $1.1M, R&D $109K; total op expenses $1.25M.
Avenue Capital facility provides up to $25M; initial $7M funded March 24, 2026; $18M available on milestones.
Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis; interim analysis Q2 2026, topline mid-2026.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001213900-26-054480

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.